Literature DB >> 10940516

The Akt/protein kinase B-dependent anti-apoptotic pathway and the mitogen-activated protein kinase cascade are alternatively activated in human glioblastoma multiforme.

J Schlegel1, G Piontek, B Budde, F Neff, A Kraus.   

Abstract

We investigated the activation of two important signal transduction pathways in human glioblastoma cells and found a constitutive phosphorylation of either Akt or mitogen-activated protein kinase (MAPK) under serum free conditions. In all but one cell line Wortmannin-sensitive activation of Akt could be attributed to the loss of functional PTEN protein. All cell lines with Akt activation exhibited only weak phosphorylation of the MAPK signal pathway, whereas those without constitutive Akt activation demonstrated high levels of phosphorylated MAPK under serum free conditions. Our data might indicate the presence of two functional subtypes of glioblastoma multiforme, since Akt and MAPK are involved in cellular survival and proliferation signalling, respectively.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940516     DOI: 10.1016/s0304-3835(00)00515-2

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

1.  TRAIL-induced apoptosis in gliomas is enhanced by Akt-inhibition and is independent of JNK activation.

Authors:  V K Puduvalli; D Sampath; J M Bruner; J Nangia; R Xu; A P Kyritsis
Journal:  Apoptosis       Date:  2005-01       Impact factor: 4.677

2.  Aldehyde dehydrogenase 1 positive glioblastoma cells show brain tumor stem cell capacity.

Authors:  Michael Rasper; Andrea Schäfer; Guido Piontek; Julian Teufel; Gero Brockhoff; Florian Ringel; Stefan Heindl; Claus Zimmer; Jürgen Schlegel
Journal:  Neuro Oncol       Date:  2010-07-13       Impact factor: 12.300

3.  Metformin inhibits leptin-induced growth and migration of glioblastoma cells.

Authors:  Rita Ferla; Eva Haspinger; Eva Surmacz
Journal:  Oncol Lett       Date:  2012-08-03       Impact factor: 2.967

4.  Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1.

Authors:  T Que; Y Song; Z Liu; S Zheng; H Long; Z Li; Y Liu; G Wang; Y Liu; J Zhou; X Zhang; W Fang; S Qi
Journal:  Oncogene       Date:  2015-01-19       Impact factor: 9.867

5.  Dual targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and induces radiosensitivity in JNK-1 expressing cells.

Authors:  Mia Carapancea; Daria Cosaceanu; Raluca Budiu; Anna Kwiecinska; Ligia Tataranu; Vasile Ciubotaru; Oana Alexandru; Monica Banita; Catalina Pisoschi; Magnus L Bäcklund; Rolf Lewensohn; Anica Dricu
Journal:  J Neurooncol       Date:  2007-06-14       Impact factor: 4.130

6.  Therapeutic potential of cyclooxygenase-3 inhibitors in the management of glioblastoma.

Authors:  Ersoy Oksuz; Fatmahan Atalar; Gamze Tanırverdi; Ayahan Bilir; Andleeb Shahzadi; Zeliha Yazici
Journal:  J Neurooncol       Date:  2015-10-27       Impact factor: 4.130

7.  Downregulation of microRNA-637 Increases Risk of Hypoxia-Induced Pulmonary Hypertension by Modulating Expression of Cyclin Dependent Kinase 6 (CDK6) in Pulmonary Smooth Muscle Cells.

Authors:  Hai-Yan Sang; Ying-Li Jin; Wen-Qi Zhang; Li-Bo Chen
Journal:  Med Sci Monit       Date:  2016-10-29

8.  Expression of p-AKT characterizes adenoid cystic carcinomas of head and neck with a higher risk for tumor relapses.

Authors:  Hans-Ullrich Völker; Matthias Scheich; Annette Berndt; Imme Haubitz; Alexandra Metzger; Hans-Konrad Müller-Hermelink; Ulrike Kämmerer; Melanie Schmidt
Journal:  Diagn Pathol       Date:  2009-06-19       Impact factor: 2.644

9.  A novel algorithm for detecting differentially regulated paths based on gene set enrichment analysis.

Authors:  Andreas Keller; Christina Backes; Andreas Gerasch; Michael Kaufmann; Oliver Kohlbacher; Eckart Meese; Hans-Peter Lenhof
Journal:  Bioinformatics       Date:  2009-08-27       Impact factor: 6.937

10.  Co-overexpression of RIOK1 and AKT1 as a prognostic risk factor in glioma.

Authors:  Yiwei Wang; Xiaochen Xie; Shu Li; Dongyong Zhang; Heyu Zheng; Min Zhang; Zhong Zhang
Journal:  J Cancer       Date:  2021-07-25       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.